Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers

scientific article published in August 2015

Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/1538-7445.AM2015-CT105

P50authorCarl H. JuneQ19277113
Simon F LaceyQ56978267
Bruce L. LevineQ85544154
David L. PorterQ110797660
P2093author name stringAndrew R. Haas
Anne Marie Nelson
Gabriela Plesa
Maureen McGarvey
Mark A. Morgan
Marcela V. Maus
Janos L. Tanyi
Gregory L. Beatty
Caitlin J. Stashwick
Mark H. O'Hara
Naseem DS Kerr
P433issue15 Supplement
P407language of work or nameEnglishQ1860
P304page(s)CT105-CT105
P577publication date2015-08-01
P1433published inCancer ResearchQ326097
P1476titleAbstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers
P478volume75

Reverse relations

cites work (P2860)
Q89321683Immunotherapy for gynecologic cancers
Q34507561Prospects for gene-engineered T cell immunotherapy for solid cancers.